Ipsen has successfully completed its first Rated Public Bond of €500 million with a 3.875% coupon maturing in March 2032, following Investment Grade ratings from S&P (BBB-) and Moody's (Baa3).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.